Research Article | Open Access
Liang Sun, Yizhou Yao, Ting Lu, Zengfu Shang, Shenghua Zhan, Weiqiang Shi, Guofeng Pan, Xinguo Zhu, Songbing He, "DAB2IP Downregulation Enhances the Proliferation and Metastasis of Human Gastric Cancer Cells by Derepressing the ERK1/2 Pathway", Gastroenterology Research and Practice, vol. 2018, Article ID 2968252, 10 pages, 2018. https://doi.org/10.1155/2018/2968252
DAB2IP Downregulation Enhances the Proliferation and Metastasis of Human Gastric Cancer Cells by Derepressing the ERK1/2 Pathway
DAB2IP (DOC2/DAB2 interactive protein) is downregulated in several cancer types, and its downregulation is involved in tumor cell proliferation, apoptosis, metastasis, and epithelial-mesenchymal transition (EMT). We aimed to investigate the potential role of DAB2IP in the development and progression of gastric cancer. DAB2IP levels were analyzed in human gastric cancer and adjacent normal tissues by Western blots and immunohistochemistry. Potential roles of DAB2IP in regulating gastric cancer cell growth and metastasis were examined by genetic manipulation in vitro. The molecular signaling was determined to understand the mechanisms of observed DAB2IP effects. DAB2IP level is lower in gastric cancer tissues as compared to paired normal tissues. Knockdown of DAB2IP enhanced gastric cancer cell growth and metastasis in vitro and promoted EMT progress at both protein and mRNA levels. Silencing DAB2IP activated extracellular signal-regulated kinase 1/2 (ERK1/2) pathway, and the enhanced proliferation and migration ability induced by DAB2IP knockdown were reduced after incubation with U0126 in SGC7901 gastric cancer cells. Inhibition of DAB2IP enhances gastric cancer cell growth and metastasis through targeting the ERK1/2 signaling, indicating that it may serve as a potential target for treatment of gastric cancer.
Gastric cancer (GC) is one of the most common malignancies and the second leading cause of cancer death worldwide [1, 2]. Though therapeutic strategies are continually improved, overall 5-year survival is still less than 30% because most gastric cancers are diagnosed at advanced or metastatic stages [3–5]. Therefore, it is urgent to explore specific and sensitive biomarkers for early diagnosis of gastric cancer, and identification of molecules suppressing metastasis of tumor cells may provide novel targets for therapy of gastric cancer.
DAB2IP (DOC2/DAB2 interactive protein), a member of the RAS-GTPase-activating protein (RAS-GAP) family , is downregulated in several cancer types, such as prostate cancer, bladder cancer, hepatocellular cancer, and colorectal cancer [7–10]. In cancers, downregulation of DAB2IP has been demonstrated to be involved in tumor cell proliferation, apoptosis, metastasis, and epithelial-mesenchymal transition (EMT) through several signaling pathways, including Ras-ERK, PI3K-Akt, ASK1-JNK, and NF-κB [7, 11–13]. However, there are just two studies focusing on DAB2IP in gastric cancer [14, 15], which indicate that DAB2IP methylation is frequently present in gastrointestinal tumors and the resulting gene silencing plays an important role in gastrointestinal carcinogenesis. These data suggest that low expression of DAB2IP contributes to the development and progression of gastric cancer, but the precise function and internal mechanisms of DAB2IP in gastric cancer cell growth and metastasis remain elusive.
Herein, we detected the expression of DAB2IP in gastric tumor tissue specimens by Western blots and immunohistochemical (IHC) staining and investigated the effect of DAB2IP knockdown on gastric cancer cell proliferation and migration in vitro. We also examined its effect on the regulation of ERK1/2 signaling pathway, which strongly associates with cell growth, metastasis, and EMT in gastric cancer [16–18]. Our in vitro studies demonstrate that DAB2IP functions as a novel regulator for ERK1/2 signaling pathway to mediate gastric cancer cell growth and metastasis and reveal its potential implications for new approaches to gastric cancer therapy.
2. Materials and Methods
2.1. Human Gastric Cancer Tissues and Cell Lines
Human gastric cancer tissues and adjacent normal tissues were collected immediately after surgical resection at the First Affiliated Hospital of Soochow University (Suzhou, Jiangsu, China). The researches were supported by the Independent Ethics Committee (IEC) of the First Affiliated Hospital of Soochow University, and all patients provided written informed consent. The human gastric cancer cell lines were all purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium (Hyclone) containing 10% FBS (Gibco), 100 units/ml penicillin G sodium, and 100 μg/ml streptomycin sulfate (Gibco). Both cells were maintained at 37°C in a humidified atmosphere containing 5% CO2.
2.2. Immunohistochemistry (IHC)
Surgical specimens were fixed in 10% formalin and embedded in paraffin. Briefly, the paraffin-embedded tissues were serially cut into 5 μm sections and incubated with the polyclonal antibody recognizing human DAB2IP at 1 : 200 dilutions 4°C overnight. The proteins were visualized using a tissue staining kit (Zhongshan Biotechnology, Beijing, China), and staining scores were examined by two clinical pathologists. Five random regions were analyzed and the presence of brown-colored granules on the cytoplasm was taken as a positive signal. The staining was divided by color intensity into not colored, light yellow, brown, and tan and is recorded as 0, 1, 2, and 3, respectively. Positive cell rate of <25% was a score of 1, positive cell rate of 25–50% was a score of 2, positive cell rate of 51–75% was a score of 3, positive cell rate of >75% was a score of 4. An average intensity score of 4 or above was considered as high expression and a score below 4 as none or low expression.
2.3. Generation of Stable Cell Lines
AGS and SGC7901 cell lines that stably expressed DAB2IP-specific short hairpin RNA (shRNA) and scrambled shRNA control were constructed using a lentivirus vector-based shRNA technique. The human DAB2IP shRNA targets are 5-GGG AUA GGC UAA GGA GUAATT-3 (shDAB2IP#1) and 5-CGC UGU AUG AGU CAG AUGATT-3 (shDAB2IP#2). Oligonucleotides were constructed in lentiviral RNAi vector (GenePharma, Shanghai, China). After cotransfection of lentiviral packaging plasmids into 293 T cells, lentivirus-containing supernatant was obtained 48 h after transfection. AGS and SGC7901 cells were transduced with serial dilutions of lentiviral supernatant and selected by 4 μg/ml puromycin for 2 weeks.
2.4. Protein Extraction and Western Blot Analysis
Whole protein extracts were lysed in ice-cold RIPA lysis buffer containing cocktails of protease and phosphatase inhibitors (Sigma) according to the manufacturer’s protocol. Total proteins from each lysate were separated by SDS-PAGE and transferred onto PVDF membranes and then blocked with 5% nonfat milk for 1 hour. The membranes were then probed with the indicated primary antibodies at 4°C with gentle shaking overnight and incubated with horseradish peroxidase- (HRP-) conjugated secondary antibodies. Then, the proteins were visualized by chemiluminescence, and signals were quantified by Image J software. Antibodies used in this study are listed in Table 1.
2.5. RNA Extraction and Quantitative Real-Time Reverse Transcription PCR (QRT-PCR)
Total RNA was extracted from cells using TRIzol Reagent (Invitrogen, Life Technologies), and cDNA was synthesized from 2 μg of RNA using the First Strand cDNA Synthesis Kit (Fermentas) according to the manufacturer’s instructions. QRT-PCR was carried out using Power SYBR® Green PCR Master Mix (ABI, USA) on the 7500 real-time PCR system (ABI, life technology). 18 s was used as a loading control for each specific gene. The sequences for sense (S) and antisense (AS) primers are as follows: human-DAB2IP-S, 5-CTGAGCGGGATAAGTGGATGG-3, human-DAB2IP-AS, 5-AAACATTGTCCGTCTTGAGCTT-3, human-E-cadherin-S, 5-CGGGAATGCAGTTGAGGATC-3, human-E-cadherin-AS, 5-AGGATGGTGTAAGCGATGGC-3, human-Vimentin-S, 5-GAGAACTTTGCCGTTGAAGC-3, human-Vimentin-AS, 5-GCTTCCTGTAGGTGGCAATC-3, human-18 s-S, 5-GTAACCCGTTGAACCCCATT-3, human-18 s-AS, 5-CCATCCAATCGGTAGTAGCG-3. The PCR conditions consisted of 5 min at 95°C 1 cycle, 30 sec at 95°C, 30 sec at 55°C, 30 sec at 72°C, and 7 min at 72°C 40 cycles. The relative fold changes in mRNA expression were calculated using the 2−∆∆CT method, where the average of ∆CT values for the amplicon of interest was normalized to that of 18 s and compared with the control specimens.
2.6. MTT Assay of Cell Viability
Cell viability was determined using an MTT assay kit (Amresco, USA). After transfection, 2000 cells were seeded in 96-well plates for 1 d, 2 d, 3 d, 4 d, and 5 d and then incubated with MTT solution-containing culture medium at 37°C for 4 hours. Then supernatants were removed, and formazan crystals were dissolved in 150 μl DMSO. After gentle shaking for 10 minutes, the absorbance at 490 nm was measured by using a microplate reader.
2.7. Colony Formation Assay
1000 cells were placed in 6-well plates for 10 days and then fixed and stained with 0.1% crystal violet. The number of foci containing >100 cells was determined at 40x magnification using an optical microscope (Nikon), and the images were taken by a digital camera (Nikon).
2.8. Cell Migration Assay
Gastric cancer cell migration was assessed using the Transwell chambers (pore size, 8.0 μm; Corning, New York, USA). The cells were resuspended in serum-free RPMI medium, then cell suspensions (200 μl containing 50,000 cells) were seeded onto the filters in 24-well chambers; 750 μl of medium containing 10% FBS was placed in the lower chambers as a chemoattractant. The cells were allowed to migrate for 24 h at 37°C. Cells remaining on the upper surface of the membrane were removed using a cotton swab. The filters were fixed with 4% paraformaldehyde, and the cells were stained with 0.1% crystal violet solution. The cells that had migrated from the upper to the lower side of the filter were counted in 5 randomly selected fields per sample.
2.9. Statistical Analysis
Data are presented as mean ± SEM. Statistical significance was analyzed using the Student t-test (unpaired, two-tailed) or one-way ANOVA. Pearson χ2 test was used to analyze the relationships between DAB2IP expression and clinicopathologic factors. A value of was considered to indicate a statistically significant difference.
3.1. Downregulation of DAB2IP in Human Gastric Cancer Correlates with Tumor Size, Lymph Node Metastasis, and TNM Stage
To investigate the potential role of DAB2IP in the development of gastric cancer, we first used Western blotting to examine DAB2IP expression in human gastric cancer tissues and paired adjacent normal tissues. Strikingly, our results showed that abundant DAB2IP expression was observed in the matched paraneoplastic tissues of gastric cancer. On the contrary, the expression of DAB2IP was obviously lower in the primary gastric cancer tumors (Figure 1(a)). Immunohistochemical staining confirmed that the expression of DAB2IP is downregulated in tumor tissues and is further reduced in those with lymph node metastasis (Figures 1(b) and 1(c)). We next investigated the relationship between DAB2IP expression levels and the clinicopathologic status of patients with gastric cancer and found that reduced DAB2IP in gastric cancer cells was significantly correlated with tumor size, lymph node metastasis, and TNM stage (Table 2). These data suggest that reduced DAB2IP expression is associated with the development of gastric cancer.
3.2. Expression of DAB2IP in Human Gastric Cancer Cells and shRNA against DAB2IP Inhibits the mRNA and Protein Levels of DAB2IP Expression
To evaluate the baseline expression levels of DAB2IP in a series of human gastric cancer cell lines, we detected the mRNA and protein expression of DAB2IP by QRT-PCR and Western blotting analysis, respectively. Our results evidenced that AGS cells and SGC7901 cells expressed a high level of DAB2IP at both mRNA and protein levels (Figure 2(a)). We then stably knocked down DAB2IP expression using a lentivirus vector-based shRNA technique in AGS and SGC7901 cell lines, and the knockdown efficiency was confirmed by Western blot and QRT-PCR analysis (Figures 2(b) and 2(c)).
3.3. DAB2IP Deficiency Promotes Gastric Cancer Cell Growth and Metastasis In Vitro
Since DAB2IP expression is downregulated in gastric cancer tissues, we thus asked whether DAB2IP has a causal role in regulating gastric cancer cell phenotypes. Colony formation assays showed that the ability of SGC7901 cells to form foci was greatly enhanced when cells lacked DAB2IP (Figures 3(a) and 3(c)). In agreement with this result, MTT assays revealed that silencing DAB2IP in SGC7901 cells significantly enhanced the ability of cell proliferation (Figure 3(b)). In a transwell migration assay, DAB2IP-depleted SGC7901 cells migrated approximately twice as much as the control cells (Figure 3(d)). These results indicate that DAB2IP deficiency promotes gastric cancer cell growth and metastasis in vitro.
3.4. Silencing DAB2IP Expression Promotes EMT Progress at Both Protein and mRNA Levels in Gastric Cancer Cells
Since DAB2IP is involved in gastric cancer metastasis, it is possible that DAB2IP may regulate EMT progress, which is an early event in the metastasis of cancer [19, 20]. To test this, the expression of the epithelial marker E-cadherin and the mesenchymal marker vimentin was analyzed using QRT-PCR and Western blotting assays. Our results revealed that silencing DAB2IP reduced E-cadherin expression but increased vimentin expression at both protein and mRNA levels (Figures 4(a), 4(b), and 4(c)), indicating that DAB2IP exerts a crucial role in modulating EMT in gastric cancer cells.
3.5. The Tumor-Promoting Effects Induced by DAB2IP Knockdown on Gastric Cancer Cells Are Mediated through the Activation of ERK1/2 Pathway
Given the evidence that ERK1/2 signaling pathway was identified as one of the most significantly altered pathway when DAB2IP was knockdown in cancers  and the ERK1/2 signaling pathway plays a central role in the process of tumor cell growth and metastasis [21–23], we sought to test whether ERK1/2 pathway is implicated in the DAB2IP-mediated gastric cancer cell growth and metastasis. As expected, we found that knockdown of DAB2IP obviously augmented the level of phosphorylated ERK1/2 (p-ERK1/2) in both AGS and SGC7901 gastric cancer cells (Figure 5(a)). To further confirm that DAB2IP regulates cell growth and EMT via ERK1/2 pathway, we treated DAB2IP-deficient cells with U0126, a highly selective inhibitor of both MEK1 and MEK2 (a type of MAPK/ERK kinase). As shown in Figure 5(b), EMT induced by DAB2IP knockdown was significantly reversed after treatment with U0126 in both AGS and SGC7901 gastric cancer cells. In agreement with this result, colony formation assays and migration assays showed that the enhanced proliferation and migration ability induced by blockade of DAB2IP were significantly reduced after incubation with U0126 in SGC7901 gastric cancer cells (Figures 5(c) and 5(d)). These data suggest that DAB2IP modulates the growth and metastasis of gastric cancer cells via regulation of ERK1/2 signaling pathway.
Recently, DAB2IP was identified as a DOC-2/DAB2 interactive protein with the growth-inhibitory effect in prostate cancer . Since then, the functions of DAB2IP have extended to regulating cell proliferation, metastasis, EMT, cancer stem cell phenotype, radiation, and chemotherapy resistance [11–13, 24–28]. DAB2IP is a member of the RAS-GTPase-activating protein (RAS-GAP) family  and is downregulated in several cancer types, including prostate cancer, bladder cancer, hepatocellular cancer, and colorectal cancer [7–10], suggesting that DAB2IP has emerged as an attractive target for cancer therapy.
However, studies focusing upon DAB2IP in gastric cancer are scanty. Previous studies [14, 15] have provided evidence that DAB2IP methylation is frequently present in gastrointestinal tumors, and the resulting gene silencing plays an important role in gastrointestinal carcinogenesis, indicating that downregulation of DAB2IP contributes to the development and progression of gastric cancer. However, the functional role of DAB2IP and the concrete molecular mechanisms in gastric cancer remain unclear and need to be explored.
Emerging literature suggests that EMT plays a crucial role in tumor cell metastasis and invasion, which is accompanied by upregulation of mesenchymal-associated genes such as vimentin and downregulation of epithelial-associated markers such as E-cadherin [19, 20]. Several types of signaling and molecules are involved in the regulation of EMT, such as transforming growth factor β (TGF-β)  Hedgehog , Notch , and MAPK/ERK [21–23].
In the present study, we demonstrated for the first time that the expression of DAB2IP in gastric cancer tissue was downregulated compared to the adjacent normal tissues. We also provided the first evidence that knockdown of DAB2IP enhanced proliferation and migration of gastric cancer cells. In view of the important role of EMT in tumor metastasis during tumor progression [19, 20], we explored the effect of DAB2IP on EMT progress and revealed that DAB2IP can modulate the expression of EMT marker E-cadherin and vimentin in AGS and SGC7901 gastric cancer cells.
Considering that DAB2IP plays a critical role in regulating the activation of ERK1/2 pathway in colorectal cancer [13, 31] and activation of ERK1/2 signaling pathway contributes to tumor cell growth and metastasis [21–23], we asked whether DAB2IP modulates the growth and metastasis of gastric cancer cells via regulating ERK1/2 signaling pathway. In accordance with other studies [13, 31], blockade of DAB2IP enhanced the phosphorylation of ERK1/2 in gastric cancer cells (Figure 5(a)) and the enhanced proliferation and migration ability induced by DAB2IP knockdown was remarkably reduced after incubation with U0126 in SGC7901 gastric cancer cells (Figures 5(c) and 5(d)). Furthermore, EMT induced by DAB2IP knockdown was reversed after treatment with U0126 in both AGS and SGC7901 gastric cancer cells (Figure 5(b)). These data indicate that DAB2IP regulates the growth, metastasis, and EMT of gastric cancer cells via regulation of ERK1/2 signaling pathway.
However, there are some limitations in our study. Firstly, we did not investigate the effect of depletion of DAB2IP on gastric cancer tumorigenesis and metastasis in vivo. Secondly, DAB2IP overexpression in gastric cancer cells was not carried out because we failed to construct the expressing vector due to the long coding domain of DAB2IP gene. Thus, more research should be undertaken to further explore the function of DAB2IP in gastric cancer.
In conclusion, our present study not only indicates that DAB2IP is downregulated in gastric cancer tissues compared to the adjacent normal tissues but also emphasizes the effect of DAB2IP knockdown on gastric cancer cell growth and metastasis in vitro. Moreover, we reveal a critical mechanism for DAB2IP in the regulation of gastric cancer tumorigenesis and metastasis through its participation in EKR1/2 signaling pathway. This may highlight a new entry point for treating gastric cancer by targeting the DAB2IP/ERK1/2 signaling axis.
Conflicts of Interest
All authors declared no conflict of interests.
This present study was supported by Project of Nature Science Foundation of China (81672348), Natural Science Foundation of Jiangsu Province of China (BK2016255), Six Major Talent Peak Project of Jiangsu Province of China (2015-WSW-014), Six One Project for Advanced Medical Talent of Jiangsu Province of China (LGY2016031), and Jiangsu Provincial Medical Youth Talent (QNRC2016735).
- E. Van Cutsem, X. Sagaert, B. Topal, K. Haustermans, and H. Prenen, “Gastric cancer,” The Lancet, vol. 388, no. 10060, pp. 2654–2664, 2016.
- G. J. Gores and D. Lieberman, “Good news–bad news: current status of GI cancers,” Gastroenterology, vol. 151, no. 1, pp. 13–16, 2016.
- R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2013,” CA: A Cancer Journal for Clinicians, vol. 63, no. 1, pp. 11–30, 2013.
- J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” International Journal of Cancer, vol. 136, no. 5, pp. E359–E386, 2015.
- R. Shridhar, K. Almhanna, S. E. Hoffe et al., “Increased survival associated with surgery and radiation therapy in metastatic gastric cancer: a surveillance, epidemiology, and end results database analysis,” Cancer, vol. 119, no. 9, pp. 1636–1642, 2013.
- H. Chen, S. Toyooka, A. F. Gazdar, and J. T. Hsieh, “Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines,” Journal of Biological Chemistry, vol. 278, no. 5, pp. 3121–3130, 2003.
- D. Xie, C. Gore, J. Liu et al., “Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 6, pp. 2485–2490, 2010.
- Y. J. Shen, Z. L. Kong, F. N. Wan et al., “Downregulation of DAB2IP results in cell proliferation and invasion and contributes to unfavorable outcomes in bladder cancer,” Cancer Science, vol. 105, no. 6, pp. 704–712, 2014.
- X. Zhang, N. Li, X. Li et al., “Low expression of DAB2IP contributes to malignant development and poor prognosis in hepatocellular carcinoma,” Journal of Gastroenterology and Hepatology, vol. 27, no. 6, pp. 1117–1125, 2012.
- J. Wang, X. Zhu, J. Hu et al., “The positive feedback between snail and DAB2IP regulates EMT, invasion and metastasis in colorectal cancer,” Oncotarget, vol. 6, no. 29, pp. 27427–27439, 2015.
- X. Dai, B. J. North, and H. Inuzuka, “Negative regulation of DAB2IP by Akt and SCFFbw7 pathways,” Oncotarget, vol. 5, no. 10, pp. 3307–3315, 2014.
- D. Xie, C. Gore, J. Zhou et al., “DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 47, pp. 19878–19883, 2009.
- L. Liu, C. Xu, J. T. Hsieh, J. Gong, and D. Xie, “DAB2IP in cancer,” Oncotarget, vol. 7, no. 4, pp. 3766–3776, 2016.
- H. Dote, S. Toyooka, K. Tsukuda et al., “Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in gastrointestinal tumour,” British Journal of Cancer, vol. 92, no. 6, pp. 1117–1125, 2005.
- S. Xu, Y. Zhou, W. D. Du et al., “Association of the variant rs2243421 of human DOC-2/DAB2 interactive protein gene (hDAB2IP) with gastric cancer in the Chinese Han population,” Gene, vol. 515, no. 1, pp. 200–204, 2013.
- Y. F. Pei, Y. J. Zhang, Y. Lei, D. W. Wu, T. H. Ma, and X. Q. Liu, “Hypermethylation of the CHRDL1 promoter induces proliferation and metastasis by activating Akt and Erk in gastric cancer,” Oncotarget, vol. 8, no. 14, pp. 23155–23166, 2017.
- S. Jia, J. Lu, T. Qu et al., “MAGI1 inhibits migration and invasion via blocking MAPK/ERK signaling pathway in gastric cancer,” Chinese Journal of Cancer Research, vol. 29, no. 1, pp. 25–35, 2017.
- Q. Zhou, X. Wang, Z. Yu et al., “Transducin (β)-like 1 X-linked receptor 1 promotes gastric cancer progression via the ERK1/2 pathway,” Oncogene, vol. 36, no. 13, pp. 1873–1886, 2017.
- D. M. Gonzalez and D. Medici, “Signaling mechanisms of the epithelial-mesenchymal transition,” Science Signaling, vol. 7, no. 344, article re8, 2014.
- M. Tania, M. A. Khan, and J. Fu, “Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer,” Tumour Biology, vol. 35, no. 8, pp. 7335–7342, 2014.
- K. Ichikawa, Y. Kubota, T. Nakamura et al., “MCRIP1, an ERK substrate, mediates ERK-induced gene silencing during epithelial-mesenchymal transition by regulating the co-repressor CtBP,” Molecular Cell, vol. 58, no. 1, pp. 35–46, 2015.
- N. Komatsu, Y. Fujita, M. Matsuda, and K. Aoki, “mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells,” Oncogene, vol. 34, no. 45, pp. 5607–5616, 2015.
- Y. Suh, C. H. Yoon, R. K. Kim et al., “Claudin-1 induces epithelial–mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells,” Oncogene, vol. 32, no. 41, pp. 4873–4882, 2013.
- Z. Wang, C. P. Tseng, R. C. Pong et al., “The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2,” Journal of Biological Chemistry, vol. 277, no. 15, pp. 12622–12631, 2002.
- E. J. Yun, S. T. Baek, D. Xie et al., “DAB2IP regulates cancer stem cell phenotypes through modulating stem cell factor receptor and ZEB1,” Oncogene, vol. 34, no. 21, pp. 2741–2752, 2015.
- Z. Kong, D. Xie, T. Boike et al., “Downregulation of human DAB2IP gene expression in prostate cancer cells results in resistance to ionizing radiation,” Cancer Research, vol. 70, no. 7, pp. 2829–2839, 2010.
- K. Wu, D. Xie, Y. Zou et al., “The mechanism of DAB2IP in chemoresistance of prostate cancer cells,” Clinical Cancer Research, vol. 19, no. 17, pp. 4740–4749, 2013.
- J. Zavadil and E. P. Böttinger, “TGF-β and epithelial-to-mesenchymal transitions,” Oncogene, vol. 24, no. 37, pp. 5764–5774, 2005.
- X. Li, W. Deng, C. D. Nail et al., “Snail induction is an early response to Gli1 that determines the efficiency of epithelial transformation,” Oncogene, vol. 25, no. 4, pp. 609–621, 2006.
- L. A. Timmerman, J. Grego-Bessa, A. Raya et al., “Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation,” Genes & Development, vol. 18, no. 1, pp. 99–115, 2004.
- X. H. Zhu, J. M. Wang, S. S. Yang et al., “Down-regulation of DAB2IP promotes colorectal cancer invasion and metastasis by translocating hnRNPK into nucleus to enhance the transcription of MMP2,” International Journal of Cancer, vol. 141, no. 1, pp. 172–183, 2017.
Copyright © 2018 Liang Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.